Evidence map›Paper›PMID 41533230›Full record

ArticleNeurochemical research2026

The Anti-proliferative Effects of Anandamide and Oleamide in Glioblastoma Cell Lines Recruit Mitochondrial and PPAR-γ Receptor Modulation.

Ana Laura Torres-Román, Alette Ortega-Gómez, Carolina Y Reyes-Soto, Omar Emiliano Aparicio-Trejo, Belén Cuevas-López, Fernando E García-Arroyo, Erika Ruíz-García, Juan A Matus-Santos, Beatriz Ferrer, Michael Aschner and 5 more

Abstract read
In one paragraph

Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Combination of Melittin andInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ana Laura Torres-RománPrograma de Posgrado (Doctorado) en Ciencias Biológicas, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico.
Alette Ortega-GómezSubdirección de Oncología y Hematología, Instituto Nacional de Cancerología, 14080, Mexico City, Mexico. ortega.alette@gmail.com.
Carolina Y Reyes-SotoPrograma de Posgrado (Doctorado) en Ciencias Biológicas, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico.
Omar Emiliano Aparicio-TrejoDepartamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, 14080, Mexico City, Mexico.
Belén Cuevas-LópezDepartamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, 14080, Mexico City, Mexico.
Fernando E García-ArroyoDepartamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, 14080, Mexico City, Mexico.
Erika Ruíz-GarcíaDirección de Docencia, Instituto Nacional deCancerología, 14080, Mexico City, Mexico.
Juan A Matus-SantosInternational Oncologic Center (COI), 04700, Mexico City, Mexico.
Beatriz FerrerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Gustavo JardónLaboratorio de Nanotecnología y Nanomedicina, Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, 04960, Mexico City, Mexico.
Tessy López-GoerneLaboratorio de Nanotecnología y Nanomedicina, Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, 04960, Mexico City, Mexico.
Anayansi Molina-HernándezSubdirección de Investigación Médica, Instituto Nacional de Perinatología, 11000, Mexico City, Mexico.
Juan Carlos Tenorio-MonterrubioCentro Oncológico de Oriente (COORI), 56363, Chimalhuacan, Estado de México, Mexico.
Abel SantamaríaFacultad de Ciencias, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico. absada@yahoo.com.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías 809272NIEHS NIH HHS R01ES03771
6 · The paper itself

Abstract

The endocannabinoid anandamide (AEA) and the related metabolite oleamide (ODA) have been demonstrated to possess anti-proliferative properties by recruiting apoptotic mechanisms in glioblastoma cells; however, the role of receptors other than the canonical cannabinoid receptors in their pattern of anti-proliferative mechanisms has been poorly investigated. Here, we evaluated the role of mitochondrial function and PPAR-γ membrane receptors in the anti-proliferative mechanisms induced by AEA and ODA in the glioblastoma cell lines C6 and RG2. Cell viability and lipid peroxidation assessments in both cell lines showed antiproliferative and pro-oxidant effects of the tested cannabinoids, respectively, compared to primary astrocyte cultures used as a non-tumor negative control. AEA and ODA also reduced mitochondrial membrane potential in C6, but not in RG2 cells, while impairing mitochondrial Complex I activity in C6. The PPAR-γ receptor antagonist GW9662 showed differential effects on the AEA- and ODA-induced loss of cell viability in both cell lines, as well as in mitochondrial membrane potential. The ontogenetic origin and metabolic differences between RG2 and C6 cell lines may establish differential responses evoked by endogenous cannabinoids and PPAR-γ receptor modulation. Combined, our results demonstrate that AEA and ODA modulate mitochondrial function in glioblastoma cells by inhibiting the activity of mitochondrial Complex 1, which in turn increases markers of oxidative damage and interferes with glioblastoma proliferation.

Indexed as

Arachidonic AcidsCell ProliferationEndocannabinoidsGlioblastomaMitochondriaOleic AcidsPolyunsaturated AlkamidesPPAR gammaAnilidesAnimalsCell Line, TumorCell SurvivalHumansMembrane Potential, MitochondrialRats2-chloro-5-nitrobenzanilideanandamideAnilidesArachidonic AcidsEndocannabinoidsOleic AcidsoleylamidePolyunsaturated AlkamidesPPAR gammaAntitumor activityBrain cancerEndocannabinoid systemMitochondrial metabolismOxidative stressPPAR-γ

Identifiers

PMID41533230
PMCPMC12804296

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.